AngioDynamics (NASDAQ:ANGO) Cut to “Hold” at Wall Street Zen

Wall Street Zen cut shares of AngioDynamics (NASDAQ:ANGO) from a buy rating to a hold rating in a report published on Saturday morning,Wall Street Zen reports.

ANGO has been the subject of several other research reports. HC Wainwright lifted their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 target price on shares of AngioDynamics in a research note on Friday. Finally, Zacks Research raised shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.50.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $11.40 on Friday. The firm has a market cap of $479.42 million, a price-to-earnings ratio of -14.62 and a beta of 0.30. The firm has a 50 day simple moving average of $15.25 and a 200-day simple moving average of $13.13. AngioDynamics has a one year low of $9.39 and a one year high of $16.29.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. The company had revenue of $80.92 million for the quarter, compared to analyst estimates of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities analysts predict that AngioDynamics will post -0.25 EPS for the current fiscal year.

Insider Activity at AngioDynamics

In related news, SVP Warren Jr sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Several large investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC purchased a new stake in shares of AngioDynamics during the 2nd quarter worth approximately $38,000. Corient Private Wealth LP acquired a new position in shares of AngioDynamics in the 2nd quarter valued at $134,000. Public Employees Retirement System of Ohio purchased a new position in shares of AngioDynamics in the 2nd quarter valued at $64,000. Bank of America Corp DE purchased a new position in shares of AngioDynamics in the 2nd quarter valued at $4,490,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new stake in AngioDynamics during the 2nd quarter worth $589,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.